Cannabis and Chronic Pain: Insights from the 2025 Pain and Palliative Care Conference

Last week, the German Pain and Palliative Care Days 2025 took place in Frankfurt. Among the numerous lectures and workshops, the use of cannabinoids was a recurring theme throughout the event. Approximately 14 million people in Germany suffer from chronic pain – a serious public health issue that severely affects daily life and is often associated with psychological burdens. It is all the more important that the use of cannabinoids in pain medicine continues to gain significance. 

Cannabinoids in Pain Therapy 

Cannabinoids work through the body’s endocannabinoid system by reducing inflammation, dampening nerve irritations, and influencing pain processing in the brain. In palliative care, they also alleviate nausea and improve sleep. 

Cannabinoids exert their effects through two main receptors. CB1 receptors, primarily found in the central nervous system, inhibit neurotransmitter release and reduce the perception of pain. CB2 receptors, primarily located in immune cells, contribute to anti-inflammatory effects by decreasing the release of pro-inflammatory cytokines. 

Cannabinoids as an Alternative or Complement to Opioids 

Studies have shown that cannabinoids can be used both as a complement to and an alternative to opioids. A 2017 patient survey with 2,897 participants reveals impressive results. 78% of respondents reported better pain reduction compared to pure opioid therapy, 88% found the side effect profile more favorable, and 97% were able to reduce their opioid dosage. These numbers highlight the potential of cannabinoids, particularly in minimizing opioid-associated risks like addiction and side effects. 

Regulatory Challenges and Future Outlook 

The motto of the congress was “Individualization instead of Standardization” – a reflection of how urgently we need to bridge the gap between scientific knowledge and the specific needs in pain therapy. Practical reports show that, despite growing acceptance of cannabinoid-based medications, doctors are often faced with strict regulations and complex procedures before they can issue prescriptions covered by statutory health insurance (GKV). 

Therefore, it is crucial to simplify the prescription processes and integrate cannabinoids more strongly into the established pain therapy guidelines. Only through targeted research and reducing regulatory barriers can we ensure that patients receive the best possible support they need. 

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,